このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

A Randomized Controlled Trial Comparing Underwater Versus Conventional Preventive Coagulation for Intraprocedural Vessel Management During Peroral Endoscopic Myotomy (POEM)

2026年5月8日 更新者：Mohan Ramchandani、Asian Institute of Gastroenterology, India

Peroral Endoscopic Myotomy (POEM) has become an established, minimally invasive therapy for achalasia and esophageal motility disorders. Submucosal tunnelling is a critical phase of POEM and requires meticulous haemostasis to avoid bleeding, loss of orientation, reduced visibility, and prolonged procedural time.

The current standard method of vessel coagulation during POEM involves conventional coagulation under CO₂ insufflation using the hybrid knife (HK). However, this approach can require additional hemostatic devices-most commonly coagulation forceps-particularly when dealing with large-calibre vessels or resistant bleeding.

A novel technique-underwater preventive coagulation-leverages water as a conductive medium. Preliminary evidence suggests that:

  • electrosurgical current in water is focalized at the interface of the vessel,
  • allowing a soft sealing of the vessel wall,
  • reducing the risk of vessel rupture or unintended deep thermal injury,
  • and potentially eliminating the need to convert to coagulation forceps. Pilot data from our center demonstrate that underwater prophylactic sealing of large vessels during POEM is feasible, safe, and associated with markedly reduced need for rescue coagulation forceps. The technique is already used in practice but lacks systematic evidence from prospective randomized trials.

This study is designed to provide high-quality evidence on whether underwater vessel coagulation improves haemostatic efficiency, reduces intra-procedural bleeding, and minimizes device changes during POEM.

All POEM procedures will be performed under general anesthesia in the supine position using Fujifilm high-definition gastroscopes with a 2.8 mm channel and transparent distal cap.

Steps (Both Arms)

  1. Identify the esophagogastric junction (EGJ).
  2. Inject saline + methylene blue submucosally.
  3. Create a 2 cm mucosal incision at 5-6 o'clock position, 10 cm above EGJ.
  4. Enter the submucosal space.
  5. Perform submucosal tunnelling down to EGJ and 2-3 cm into cardia.

  6. Perform vessel haemostasis according to group allocation:

    • Underwater coagulation (intervention)
    • CO₂-based conventional coagulation (control)
  7. Perform circular myotomy (with occasional full-thickness myotomy when indicated).
  8. Close the mucosal entry using hemostatic clips.
  9. Record procedure time, instrument exchanges, bleeding events, and forceps usage.

Equipment

  • Hybrid Knife (Erbe Elektromedizin GmbH)
  • VIO 3 generator + ERBEJet 2 water-jet system
  • Methylene-blue tinted saline
  • Electrosurgical settings: ENDO CUT Q 2-3-3 for mucosal incision and myotomy

調査の概要

状態

募集

条件

介入・治療

詳細な説明

Primary Objective

To compare the proportion of POEM patients requiring rescue haemostasis with coagulation forceps (for active bleeding) between:

1. Underwater preventive vessel coagulation, and 2. Conventional vessel coagulation under CO₂ insufflation. Secondary Objectives

  1. To compare composite forceps use (rescue + prophylactic) between groups.
  2. To evaluate the frequency of prophylactic-only forceps use.
  3. To compare total number of forceps applications per procedure.
  4. To determine differences in intra-procedural bleeding episodes.
  5. To compare procedural efficiency (procedure time, number of instrument exchanges).
  6. To compare hematological and inflammatory markers (Hb drop, Hct, CRP, WBC).
  7. To compare delayed bleeding rates within 30 days.
  8. To evaluate overall complication rates (intra- and post-procedural).
  9. To assess patient-reported outcomes (pain, tolerability). A prospective, randomized, open-label, parallel-group, controlled clinical trial.

Study Arms Intervention Arm: Underwater Coagulation

  • Vessel coagulation performed entirely underwater using the Hybrid Knife.
  • SWIFT COAG: E3 (89 W) for POEM.
  • Physiological saline instilled to completely displace air around the target vessel.

Control Arm: Conventional Coagulation (CO₂ Setting)

  • Standard vessel isolation and coagulation under CO₂ insufflation.
  • SWIFT COAG: E3 (89 W) for POEM.

研究の種類

観察的

入学 (推定)

120

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

研究場所

  • インド
    • Telangana
      • Hyderabad、Telangana、インド、500082
        • 募集
        • Asian Institute of Gastroenterology Hospital
        • コンタクト：
        • コンタクト：

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

サンプリング方法

確率サンプル

調査対象母集団

120 (60 in each arm)

説明

Inclusion Criteria:

  1. Age ≥ 18 years
  2. Diagnosis of achalasia or esophageal motility disorder planned for POEM
  3. Ability to provide informed consent

Exclusion Criteria:

  1. Anticoagulant or antithrombotic therapy not safely stoppable
  2. Known coagulopathy or platelet disorder
  3. Esophageal/gastric varices
  4. Previous POEM or Heller's myotomy
  5. Prior treatment for same condition
  6. Inability or refusal to consent
  7. Visualized vessels smaller than the HK inner diameter (1.2 mm)

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか？

デザインの詳細

コホートと介入

グループ/コホート
介入・治療
Under Water Coagulation

Intervention Arm: Underwater Coagulation

  • Vessel coagulation performed entirely underwater using the Hybrid Knife.
  • SWIFT COAG: E3 (89 W) for POEM.
  • Physiological saline instilled to completely displace air around the target vessel.
他の：Under Water Preventive Coagulation

Leverages water as a conductive medium. Preliminary evidence suggests that:

  1. electrosurgical current in water is focalized at the interface of the vessel,
  2. allowing a soft sealing of the vessel wall,
  3. reducing the risk of vessel rupture or unintended deep thermal injury,
  4. and potentially eliminating the need to convert to coagulation forceps.
Conventional Coagulation

Control Arm: Conventional Coagulation (CO₂ Setting)

  • Standard vessel isolation and coagulation under CO₂ insufflation.
  • SWIFT COAG: E3 (89 W) for POEM.

この研究は何を測定していますか？

主要な結果の測定

結果測定
メジャーの説明
時間枠
To compare the proportion of POEM patients requiring rescue haemostasis with coagulation forceps (for active bleeding) between:
時間枠：60 minutes
  1. Underwater preventive vessel coagulation, and
  2. Conventional vessel coagulation under CO₂ insufflation.
60 minutes

二次結果の測定

結果測定
メジャーの説明
時間枠
To compare composite forceps use (rescue + prophylactic) between groups.
時間枠：60 minutes

To compare the proportion of POEM patients requiring rescue haemostasis with coagulation forceps (for active bleeding) between:

1.Underwater preventive vessel coagulation, and Conventional vessel coagulation under CO₂ insufflation
60 minutes
To evaluate the frequency of prophylactic-only forceps use.
時間枠：60 minutes

To compare the proportion of POEM patients requiring rescue haemostasis with coagulation forceps (for active bleeding) between:

1.Underwater preventive vessel coagulation, and Conventional vessel coagulation under CO₂ insufflation
60 minutes
To compare total number of forceps applications per procedure.
時間枠：60 minutes

To compare the proportion of POEM patients requiring rescue haemostasis with coagulation forceps (for active bleeding) between:

1.Underwater preventive vessel coagulation, and Conventional vessel coagulation under CO₂ insufflation
60 minutes
To determine differences in intra-procedural bleeding episodes
時間枠：60 minutes

To compare the proportion of POEM patients requiring rescue haemostasis with coagulation forceps (for active bleeding) between:

1.Underwater preventive vessel coagulation, and Conventional vessel coagulation under CO₂ insufflation
60 minutes
To compare procedural efficiency (procedure time, number of instrument exchanges
時間枠：60 minutes

To compare the proportion of POEM patients requiring rescue haemostasis with coagulation forceps (for active bleeding) between:

1.Underwater preventive vessel coagulation, and Conventional vessel coagulation under CO₂ insufflation
60 minutes
To compare hematological and inflammatory markers (Hb drop, Hct, CRP, WBC)
時間枠：24 hours

To compare the proportion of POEM patients requiring rescue haemostasis with coagulation forceps (for active bleeding) between:

1.Underwater preventive vessel coagulation, and Conventional vessel coagulation under CO₂ insufflation
24 hours
To compare delayed bleeding rates
時間枠：30 days
To compare the proportion of POEM patients requiring rescue haemostasis with coagulation forceps (for active bleeding) between:1.Underwater preventive vessel coagulation, and Conventional vessel coagulation under CO₂ insufflation
30 days
To evaluate overall complication rates (intra- and post-procedural)
時間枠：24 hours

To compare the proportion of POEM patients requiring rescue haemostasis with coagulation forceps (for active bleeding) between:

1.Underwater preventive vessel coagulation, and Conventional vessel coagulation under CO₂ insufflation
24 hours
To assess patient-reported outcomes (pain, tolerability).
時間枠：72 hours

To compare the proportion of POEM patients requiring rescue haemostasis with coagulation forceps (for active bleeding) between:

1.Underwater preventive vessel coagulation, and Conventional vessel coagulation under CO₂ insufflation
72 hours

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

Asian Institute of Gastroenterology, India

捜査官

  • スタディディレクター：Mohan Dr Ramchandani, MD DM、Asian Institute of Gastroenterology

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年2月1日

一次修了 (推定)

2027年5月10日

研究の完了 (推定)

2027年12月30日

試験登録日

最初に提出

2026年5月4日

QC基準を満たした最初の提出物

2026年5月4日

最初の投稿 (実際)

2026年5月8日

学習記録の更新

投稿された最後の更新 (実際)

2026年5月12日

QC基準を満たした最後の更新が送信されました

2026年5月8日

最終確認日

2026年5月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • POEM UWC 2026

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する